Business Services Industry

The Seattle Times Business Digest Column.

Knight Ridder/Tribune Business News, January, 2002

The Seattle Times Knight Ridder/Tribune Business News

Jan. 11-- SEATTLE--CORIXA'S STOCK DIVES 16 PERCENT: Investors knocked down Corixa's stock by 16 percent yesterday after the Seattle biotech company faced the latest in a series of regulatory delays holding back its first drug.

Corixa's stock fell $2.39, closing at $12.38 yesterday.

Any rebound in the company's fortune depends squarely on what happens at the Food and Drug Administration. Because the FDA is increasingly being seen as overwhelmed with drug applications, Corixa officials don't know when the agency will schedule a hearing for Bexxar, Corixa's treatment for non-Hodgkin's lymphoma.

Corixa Chief Executive Steve Gillis said Bexxar approval remains the company's...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement